Emavusertib + Ibrutinib
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed Hematologic Malignancy
Conditions
Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
Trial Timeline
Dec 28, 2017 → Oct 1, 2026
NCT ID
NCT03328078About Emavusertib + Ibrutinib
Emavusertib + Ibrutinib is a phase 1/2 stage product being developed by Curis for Relapsed Hematologic Malignancy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03328078. Target conditions include Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed Hematologic Malignancy were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
9
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03328078 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Relapsed Hematologic Malignancy